142 related articles for article (PubMed ID: 27698792)
1. Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia.
Butrym A; Rybka J; Baczyńska D; Poręba R; Mazur G; Kuliczkowski K
Oncol Lett; 2016 Oct; 12(4):2296-2300. PubMed ID: 27698792
[TBL] [Abstract][Full Text] [Related]
2. Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.
Butrym A; Rybka J; Baczyńska D; Poręba R; Kuliczkowski K; Mazur G
Oncotarget; 2016 May; 7(21):30250-7. PubMed ID: 26862847
[TBL] [Abstract][Full Text] [Related]
3. Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Butrym A; Rybka J; Baczyńska D; Tukiendorf A; Kuliczkowski K; Mazur G
Biomark Med; 2015; 9(5):453-60. PubMed ID: 25620533
[TBL] [Abstract][Full Text] [Related]
4. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients.
Butrym A; Rybka J; Baczyńska D; Tukiendorf A; Kuliczkowski K; Mazur G
J Exp Clin Cancer Res; 2015 Jul; 34(1):68. PubMed ID: 26126974
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
6. Low expression of microRNA-340 confers adverse clinical outcome in patients with acute myeloid leukemia.
Wang Q; Feng T; Xu J; Miao MH; Ji XQ; Zhu H; Shao XJ
J Cell Physiol; 2019 Apr; 234(4):4200-4205. PubMed ID: 30171606
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
8. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia.
Bi L; Sun L; Jin Z; Zhang S; Shen Z
Oncol Lett; 2018 Apr; 15(4):5611-5619. PubMed ID: 29552198
[TBL] [Abstract][Full Text] [Related]
10. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia.
Bai J; Guo A; Hong Z; Kuai W
Onco Targets Ther; 2012; 5():213-9. PubMed ID: 23055746
[TBL] [Abstract][Full Text] [Related]
12. Circular RNA profile of acute myeloid leukaemia indicates circular RNA annexin A2 as a potential biomarker and therapeutic target for acute myeloid leukaemia.
Ding Y; Dong Y; Lu H; Luo X; Fu J; Xiu B; Liang A; Zhang W
Am J Transl Res; 2020; 12(5):1683-1699. PubMed ID: 32509169
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic significance of serum miR-203 in patients with acute myeloid leukemia.
Zheng Z; Rong G; Li G; Ren F; Ma Y
Int J Clin Exp Pathol; 2019; 12(5):1548-1556. PubMed ID: 31933972
[TBL] [Abstract][Full Text] [Related]
14. Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia.
Yan J; Wu G; Chen J; Xiong L; Chen G; Li P
Cancer Biomark; 2018; 22(1):73-78. PubMed ID: 29439315
[TBL] [Abstract][Full Text] [Related]
15. Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.
Yang DQ; Zhou JD; Wang YX; Deng ZQ; Yang J; Yao DM; Qian Z; Yang L; Lin J; Qian J
Int J Lab Hematol; 2017 Feb; 39(1):42-50. PubMed ID: 27577964
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of MiR-34a/b/c Expression with Treatment Response and Prognosis of Elderly Patients with Acute Myeloid Leukemia].
Li H; Bao HX; Qin J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):476-483. PubMed ID: 32319382
[TBL] [Abstract][Full Text] [Related]
18. High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia.
Fang Z; Wang X; Wu J; Xiao R; Liu J
Cancer Biomark; 2020; 27(1):1-9. PubMed ID: 31594209
[TBL] [Abstract][Full Text] [Related]
19. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
20. Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review.
Bhatnagar B; Garzon R
Front Oncol; 2021; 11():679022. PubMed ID: 34458136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
